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The incidence of chronic allergic dermatitis is rapidly
increasing. Regulatory control of this disease has not
been adequately explored. Here we report that mast
cell-derived interleukin-2 (IL-2) contributes to the
suppression of chronic allergic dermatitis. Mice defi-
cient in IL-2 production, or deficient in mast cells
(KitW-sh/W-sh), showed exacerbated dermatitis upon
repeated oxazolone challenge when compared to
their wild-type counterparts. Adoptive transfer of
wild-type, but not Il2-/-, mast cells into KitW-sh/W-sh
mice dampened the inflammatory response. During
the course of disease, mast cell expansion occurred
at the site of inflammation and also in the spleen,
where production of IL-2 by mast cells was markedly
enhanced. In the absence of mast cell IL-2 produc-
tion, the ratio of activated to regulatory T cells at
the site of inflammation was increased. Thus,
MC-derived IL-2 contributes to the maintenance of
suppression in chronic allergic skin inflammation.
INTRODUCTION
Eczematous dermatitis is a chronic inflammatory skin disease,
associated with cutaneous hyperreactivity, which usually occurs
in individuals with an allergic background (also referred to as
atopic dermatitis [AD]). One of its most striking features is the
rising incidence during the past two decades, currently ap-
proaching 15%–30% of children at some point during childhood
(Bieber, 2008; Schultz Larsen et al., 1996). Both genetic and
environmental factors contribute to the development of AD
(Bieber, 2008; Leung et al., 2007), but the underlying mecha-
nisms by which such factors contribute to the pathogenesis of
dermatitis are poorly defined.
Animalmodels havebeenvaluable in studying themechanisms
underlying the development and severity of dermatitis. Current
models can be divided into three groups consisting of sponta-
neous dermatitis, genetically engineered mice, and hapten-
induced inflammation (Jin et al., 2009). In this latter category,
haptens such as oxazolone (Matsumoto et al., 2004) and dinitro-
fluorobenzene (DNFB) (Phanuphak et al., 1974) are used to562 Immunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc.induce skin disease in a convenient and reproducible manner.
Oxazolone inducesaTcell-dependent allergic contact hypersen-
sitivity withmast cell (MC) involvement (Evans et al., 1971; Pritch-
ard andMicklem, 1972) but in the course of repeated challenges,
it evolves into a chronic allergic inflammatory response similar to
human AD (Matsumoto et al., 2004). In hairless mice (hr/hr),
chronic treatment with oxazolone results in dermatitis that
demonstrates barrier abnormalities, a T helper 2 cell (Th2 cell)-
predominant inflammation, MC- and eosinophil-rich infilitrates,
as well as elevated IL-4 and IgE (Man et al., 2008), all hallmarks
of human AD. However, the mechanistic roles played by some
of these features in the chronicity of disease are unexplored.
MCs can enhance inflammation not only in allergic diseases
(Kalesnikoff and Galli, 2008) but also in autoimmune models
such as experimental autoimmune encephalomyelitis (Secor
et al., 2000). Alternatively, they canact as suppressors asdemon-
strated in their contribution to skin allograft tolerance (Lu et al.,
2006). MCs can also exert stimulatory or inhibitory effects on
both effector and regulatory T (Treg) cells (Galli et al., 2008; Gri
et al., 2008; Hershko and Rivera, 2010; Mekori and Metcalfe,
1999). The potential mediators of MC-T cell communication are
numerous and include secreted cytokines, chemokines, leukotri-
enes, and histamine as well as varied surface molecules (Bache-
let and Levi-Schaffer, 2007; Hershko and Rivera, 2010; Nakae
et al., 2006). The putative anatomical sites where the interaction
between these two cell types takes place are also varied and
may include such tissues as the skin (Lu et al., 2006), draining
and remote lymph nodes (LN) (Gri et al., 2008), and spleen as
well as other sites that harbor these cells.
The expanding prevalence of AD and the considerable gaps in
understanding its etiology and the regulation of its severity
prompted us to investigate the strategic players that govern
disease intensity. Here we report that MCs are protective in
late stages of oxazolone-induced chronic allergic dermatitis.
Protection occurs by a previously unrecognized regulatory
mechanism in which MC-derived IL-2 is required to maintain
the appropriate ratio of activated T cells to Treg cells at the
site of inflammation during the chronic phase of disease.
RESULTS
IL-2 Controls the Severity of Chronic Allergic Dermatitis
Induction of oxazolone-induced chronic allergic dermatitis in
mice recapitulates many of the characteristics of human AD
Figure 1. IL-2 Is Important in Suppression of Oxazolone-Induced
Chronic Dermatitis
(A) Ear swelling during induction of disease in 8- to 10-week-old Il2/ and
Il2+/+ mice (n = 4 mice/group) (top). Total IgE levels (bottom left) and ox-
azolone-specific (Oxaz sp) IgE (bottom right) as measured in the serum by
ELISA.
(B) Disease course in WT C57BL/6 mice that were injected with anti-CD25
presensitization on day -1 (n = 5 mice/group) or postsensitization on day 7
(n = 4). Data are reported beginning at the day of challenge where detectable
ear swelling might be expected. Each experiment was performed twice.
(C) Sections of ear tissue (left) stained as indicated and quantitation of
epidermal thickening (right). Abbreviations: epi, epidermis; col, collagen. Scale
bars represent 50 mm.
Statistical analysis was by two-way ANOVA (B) or by a two-tailed Student’s
t test (A and C [right]). Results are means ± SEM. **p < 0.01; ***p < 0.001. See
also Figure S1.
Immunity
Mast Cell IL-2 Suppresses Dermatitis(Leung et al., 2004), which prompted us to use this model as
a tool for investigating regulatory processes.
IL-2 is a key cytokine for Treg cell function (Malek and Bayer,
2004), which has been implicated in the control of allergic
disease, particularly asthma (Boudousquie´ et al., 2009; Curotto
de Lafaille et al., 2008; Wilson et al., 2008). Il2/ mice were
used as an initial tool to investigate the regulatory features in
control of chronic allergic dermatitis. On a C57BL/6 background,
these animals exhibit a 40% reduction in Treg cells (Zheng et al.,
2007) and have a profound impairment in Treg cell function
(Malek and Bayer, 2004). In contrast to Foxp3sf mice, the Il2/
mice have a longer life span, do not suffer from spontaneous
dermatitis, and are thus a preferable model for hapten-induceddisease. When exposed to oxazolone, severe ear swelling was
noted in Il2/ mice (Figure 1A, top). Hyperresponsiveness was
accompanied by elevated total IgE titers and overproduction of
oxazolone-specific IgE (Figure 1A, bottom). Given the known
spontaneous manifestation of inflammation in these genetically
altered mice (Sadlack et al., 1995), we confirmed the role of
IL-2 through administration of a CD25 monoclonal antibody
(Kohm et al., 2006). This antibody binds to the alpha chain of
the IL-2 receptor (IL-2R), which is constitutively expressed on
Treg cells, and causes transient inactivation (Kohm et al.,
2006). Injection of anti-CD25 prior to sensitization with oxazo-
lone resulted in enhanced inflammation at a late stage of the
disease relative to the control injection of isotype identical IgG.
This was manifested as a sustained increase in ear thickness
(Figure 1B, left), at a range previously reported as physiologically
significant (Grimbaldeston et al., 2007), as well as expansion of
dermatitis to the adjacent skin (not shown). When antibodies
were administered 1 week after sensitization, only a minimal
effect on disease course was observed (Figure 1B, right). Exam-
ination of tissue sections disclosed that oxazolone-induced
epidermal hyperplasia and collagen deposition are considerably
enhanced after anti-CD25 administration (Figure 1C). Collec-
tively, these experiments indicate that IL-2 is vital to the control
of oxazolone-induced dermatitis.
MCs Suppress Oxazolone-Induced Dermatitis
Weexplored the role ofMCs in the oxazolone-induced dermatitis
by using MC-deficient KitW-sh/W-sh mice (Grimbaldeston et al.,
2005). After five challenges with oxazolone, ear swelling was
markedly increased in KitW-sh/W-sh mice, compared to their WT
counterparts (Figure 2A, left). Adoptive transfer of WT bone
marrow-derived MCs into the ear skin of KitW-sh/W-sh mice re-
sulted in reduced ear swelling (Figure 2A, right), demonstrating
that MCs dampened inflammation. Similarly, disease suppres-
sion was observed after the administration of IL-2-anti-IL-2
complexes, a manipulation known to increase the bioavailability
of IL-2 and to promote Treg cell expansion (see Figure S1 avail-
able online; Kamimura et al., 2006; Wilson et al., 2008). Histolog-
ical analysis of tissues from KitW-sh/W-sh mice revealed that, after
intradermal (i.d.) reconstitution with MCs, engraftment occurs in
the skin of the ear as well as in the cervical draining LN and
spleen (Figures 2B and 2C). No MCs were found in LNs or
spleens of unreconstituted KitW-sh/W-sh mice, but an occasional
MC was found in ear skin, in mice with dermatitis (data not
shown). After reconstitution, the distribution of MCs was similar
to that of WT mice, although more MCs were found in the LNs of
KitW-sh/W-sh relative to WT mice while the latter mice had more
MCs in the ear (Figure S2). In both types of mice, induction of
dermatitis caused an accumulation of MCs in the (ear) skin and
an apparent redistribution of MCs from the subcapsular sinus
to the LN cortex (Figure 2B). In reconstituted KitW-sh/W-sh mice,
no MCs were found in tissues far from the site of inflammation,
like a distal (brachial) LN or in the stomach (Figure 2C). However,
MCswere observed in the spleens of unchallengedWTmice and
i.d. reconstituted KitW-sh/W-sh mice, and for both, their numbers
increased after oxazolone treatment. This accumulation was
intriguing because of the fact that the spleen did not show
dynamic changes in total cell numbers or even in CD4+ T cells,
with the exception of a modest but distinct increase in Treg cellsImmunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc. 563
Figure 2. MCs Suppress Dermatitis and Expand in the Spleen
(A) Comparison of ear swelling between KitW-sh/W-sh (n = 7 mice/group) and
C57BL/6 (WT) mice (n = 6) (left) or KitW-sh/W-sh mice i.d. injected with C57BL/6-
derived MCs (n = 5) (right). Graphs are from the same experiments but pre-
sented individually in comparison to WT for clarity. Two independent experi-
ments were performed. Statistical analysis was by two-way ANOVA.
(B) Toluidine blue staining for MC in the ear skin and draining cervical lymph
node (LN). Tissues were harvested from WT and KitW-sh/W-sh mice i.d. injected
with WT MCs after full treatment with oxazolone. Scale bars represent
200 mm.
(C) Quantitation of MC numbers in tissues distal to the inflammatory site. All
tissues were collected after completion of chronic dermatitis induction. HPF,
high power field, 3200.
Statistical significance was determined by a two-tailed Student’s t test.
Results (A andC) aremeans ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S2.
Immunity
Mast Cell IL-2 Suppresses Dermatitis(Figure S2). Because MCs were introduced only into the ears of
KitW-sh/W-sh mice, this finding argues that MCs migrate from the
skin to the draining LN and then to the spleen but not to the
brachial LN or the stomach. This view was further supported
by i.d. injection of small numbers of GFP-expressing BMMCs
in the ear skin of KitW-sh/W-sh mice, because these MCs were
found to migrate to the draining LNs and the spleen with
concomitant disease suppression (Figure S3).
Dermatitis Is Enhanced by the Spleen and Dampened
by Splenic MCs
The observation of increased MC recruitment to the spleen (Fig-
ure 2C) upon oxazolone challenge of WT or i.d. reconstituted564 Immunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc.KitW-sh/W-sh mice led us to explore the relevance of the spleen
and of MCs within it to disease regulation. Mice skewed toward
Th1 (C57BL/6) or Th2 (BALB/c) cell responses were assessed for
accumulation of MCs in the spleen upon oxazolone challenge.
As shown in Figure S4A, C57BL/6 or BALB/c mice developed
a similar response to oxazolone challenge, although BALB/c
mice had a more rapid onset. Both strains of mice showed
marked changes in MC numbers in the ear skin and the draining
LN after oxazolone challenge (Figures S4B and S4C). Although
the absolute numbers of spleen-resident MCs differed consider-
ably in the two strains (Figure S4D), oxazolone challenge
increased their numbers by approximately 3- to 5-fold in both
strains (Figure S4E). This shows that oxazolone-induced derma-
titis followed a similar pattern in both C57BL/6 and BALB/c mice
and caused an increase of MCs in the spleen of both strains.
To explore the role of the spleen in the course of disease, wild-
type (C57BL/6) mice were splenectomized and challenged with
oxazolone. These mice developed a mild allergic dermatitis rela-
tive to their WT controls (Figure 3A) and were resistant to presen-
sitization injection of anti-CD25 (Figure 3A). These findings
demonstrated that the spleen enhances the inflammatory
response and that the increased inflammation that results from
blocking the IL-2 receptor also requires the spleen. Conversely,
splenectomy did not affect the response of draining LNs (Fig-
ure 3B) and oxazolone-specific IgE production (Figure S5A)
upon oxazolone challenge and administration of anti-CD25.
Likewise, CD4+ T cell and Treg cell proliferation in the LN were
not affected by the absence of a spleen (Figure S5B). To directly
address whether the suppression mediated by MCs was inde-
pendent of their localization to the skin, we adoptively trans-
ferred MCs into KitW-sh/W-sh mice by intravenous (i.v.) injection.
As previously described (Grimbaldeston et al., 2005), the i.v.
introduction of MCs failed to reconstitute the ear pinna and these
cells were not recruited to the ear after oxazolone challenge (Fig-
ure 3C), whereas the spleen of i.v. injected mice showed large
numbers of MCs relative to their WT counterparts (Figure 3C).
When challenged, KitW-sh/W-sh mice i.v. reconstituted with MCs
showed amarked reduction in dermatitis relative toMC-deficient
KitW-sh/W-sh mice (Figure 3D), as well as milder epidermal hyper-
plasia (Figure S6). Furthermore, splenectomized KitW-sh/W-sh
mice mounted an attenuated response to oxazolone, with no
additional alleviation after MC reconstitution (Figure 3E). In this
experiment, however, we introduced MCs i.d. to ensure engraft-
ment, because i.v. injected cells showed a strong predilection for
the spleen and its removal altered reproducible engraftment.
Regardless, the findings demonstrate that the spleen contrib-
utes to the inflammation induced by oxazolone challenge and
that the presence of MCs in the spleen is associated with
suppression of chronic allergic dermatitis.
IL-2R Blockade Enhances IgE-Dependent Accumulation
of Splenic MCs
Having found that presensitization treatment with anti-CD25
inhibits regulationof disease (Figure 1B),weexamined the impact
of this manipulation on the expansion of MCs in the spleen.
Consistent with our previous result (Figure 2C), MC numbers in
the spleen increased with oxazolone treatment and were further
elevated when IL-2R was inactivated by anti-CD25 treatment
(Figure 4A). Oxazolone-specific IgE also increased in a similar
Figure 3. The Spleen Exacerbates Dermatitis and Facilitates Anti-
CD25 Enhancement or MC Suppression of Disease
(A) Splenectomized (Spleen) C57BL/6 (WT) mice (n = 5) were treated with
either control IgG or anti-CD25 and with oxazolone to induce dermatitis. Ear
swelling was compared to nonsplenectomized (Spleen+) littermates.
(B) Draining cervical LNs were harvested for evaluation of total cell numbers.
The LNs were extracted from normal and splenectomized mice shown in (A)
after full treatment with acetone or oxazolone.
(C) MCs were introduced through the tail vein prior to induction of oxazolone
dermatitis, and tissues from the inflamed ear, draining lymph nodes (LN), and
spleens (SPL) were stained with toluidine blue. Scale bars represent 100 mm.
(D) Disease course in WT, KitW-sh/W-sh, or KitW-sh/W-sh mice after i.v. injection of
MCs (n = 5). Two independent experiments were conducted.
(E) Comparison of ear swelling betweenKitW-sh/W-shmice and KitW-sh/W-sh mice
after splenectomy or splenectomy and i.d. MC reconstitution (n = 5).
Statistical analysis was done by a two-way ANOVA test (A, D, and E) or by
a two-tailed Student’s t test (B). Results are means ± SEM. ***p < 0.001. See
also Figure S3.
Figure 4. MC Recruitment and Disease Suppression Is IgE Depen-
dent
(A) Comparison between MC recruitment to the spleen (n = 6) and oxazolone-
specific (Oxaz sp) IgE levels in the serum (n = 4) of C57BL/6 mice treated with
oxazolone. Dermatitis was induced after presensitization treatment of mice
with either control IgG or anti-CD25.
(B) Kinetics of IgE and MC accumulation in the spleens of BALB/c mice, as
measured on days 0, 17, and 27 of oxazolone dermatitis (n = 4).
(C) MC numbers in the spleens of control (acetone) or oxazolone-challenged
IgE-deficient (Igh-7/) in the absence (IgG only) or in the presence of anti-
CD25 (n = 5).
(D) Disease course in Igh-7/ mice, as compared to C57BL/6 wild-type
controls (Igh-7+/+) (n = 5).
(E) Quantitation of MCs in the ears of the mice in (D).
Three independent experiments were performed. Statistical analysis was by
a two-tailed Student’s t test (A, C, and E) or by two-way ANOVA (D). Results
are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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Mast Cell IL-2 Suppresses Dermatitismanner. Analysis of oxazolone-specific IgE in the spleen prior to,
midcourse, and during the full course of disease revealed a time-
dependent increase that mirrored the increase of MCs in the
spleen (Figure 4B). To assess whether IgE was important for
the increased numbers of MCs in the spleen, we challenged the
IgE-deficient (Igh-7/) mice with oxazolone in the presence of
active or inactive (anti-CD25-treated) IL-2R. As shown in Fig-
ure 4C, accumulation of MCs in the spleen was absent in chal-
lenged Igh-7/ mice and the administration of anti-CD25 did
not substantially change MC numbers, demonstrating that IgE
production was required for MC accumulation in the spleen.
Moreover, oxazolone challenge of Igh-7/ mice resulted inmore severe eczematous dermatitis than seen in Igh-7+/+ mice
(Figure 4D). However, unlike the spleen, MC accumulation in
the ear was equal in both Igh-7+/+ and Igh-7/mice (Figure 4E),
suggesting that MC numbers in the ears are not associated with
disease suppression. Collectively, the findings show that the
IgE-dependent recruitment of MCs to the spleen is associated
with disease suppression.Chronic Oxazolone-Challenged KitW-sh/W-sh Mice
Are Hypersensitive to IL-2R Blockade
Given the importance of IL-2 in regulating the severity of the
dermatitis, we investigated whether IL-2 function might be
altered in KitW-sh/W-sh mice. Treg cells are highly dependent on
IL-2 and analysis of cells from the spleen, LN, and ear of unchal-
lenged KitW-sh/W-sh mice revealed no significant difference in theImmunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc. 565
Figure 5. MCs Cooperate with Treg Cells in Disease Suppression
(A) Flow cytometric analysis of total cell populations extracted from tissues
and stained for CD4 and Foxp3 (SPL, spleen; LN, cervical lymph node).
Statistical analysis was by a two-tailed Student’s t test. ns, not significant; nd,
not detectable.
(B) Ear swelling in C57BL/6 and KitW-sh/W-sh treated with oxazolone after pre-
sensitization injection with either control IgG or anti-CD25 (n = 5). Data are
presented as mean ± SEM; statistical significance was determined by a two-
way ANOVA, ***p < 0.01.
(C) Representative draining lymph nodes from mice with oxazolone dermatitis
and corresponding H&E-stained sections. The circle indicates hemorrhage
within the lymph node. Scale bars represent 50 mm.
See also Figure S5.
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Mast Cell IL-2 Suppresses Dermatitistotal CD4+ cells or in the proportion of CD4+Foxp3+ Treg cells
when compared to unchallenged WT control mice (Figure 5A).
Few CD4+ cells were found in the ears of unchallenged control
and KitW-sh/W-sh mice and Treg cells were not detectable in the
ear (Figure 5A). This observation indicated that Treg cell homeo-
stasis in naive animals is independent ofMCs, implying no defect
in IL-2 homeostasis. However, this did not rule out the possibility
that under conditions of repeated oxazolone challenges, MCs
are required to maintain adequate IL-2 production. In order
to assess the extent of IL-2 function in the absence of MCs,
KitW-sh/W-sh and control WT mice were injected with anti-CD25
and subsequently challenged with oxazolone. As shown in Fig-
ure 5B, WT mice treated with anti-CD25 showed a strikingly
similar profile of disease intensity to MC-deficient KitW-sh/W-sh
mice. However, when KitW-sh/W-sh mice were treated with anti-566 Immunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc.CD25 and were subsequently challenged with oxazolone, an
exaggerated disease was observed when compared to the
KitW-sh/W-sh mice injected with control IgG or control WT mice in-
jected with anti-CD25. Occasionally, the cervical draining LNs in
this group ofmice became hemorrhagic and necrotic (Figure 5C),
reflecting the physiological severity of the inflammatory
response. Thus, although MCs do not appear to be required
for Treg cell homeostasis in naive animals, at the chronic stage
of dermatitis, MCs appear to support IL-2-mediated Treg cell
responses. To assess this possibility, we quantitated the
numbers of Foxp3+ cells in the ear skin of oxazolone-challenged
KitW-sh/W-sh mice or MC-reconstituted KitW-sh/W-sh mice.
Whereas no Foxp3+ cells were observed in the ear skin of
unchallenged KitW-sh/W-sh mice (Figure 5A), oxazolone challenge
led to recruitment of Foxp3+ cells in the ear skin and reconstitu-
tion of KitW-sh/W-sh mice with MCs increased the numbers of Treg
cells at this site (Figure S7A). These findings argue that MCs
contribute to Treg cell-mediated suppression of chronic allergic
dermatitis at a late stage of disease.
MC IL-2 Production Supports Treg Cell-Mediated
Disease Suppression
Given that MCswere necessary to promote disease suppression
and caused increased Treg cell numbers at the site of inflamma-
tion, we examined the hypothesis that MCs could mediate
suppression by providing IL-2 to control the balance between
Treg cells and activated T cells in the context of oxazolone-
induced chronic dermatitis. FcεRI stimulation of MCs induced
significant levels (50–100 pg/ml) of IL-2 secretion in both BMMCs
and peritoneal-derived cultured MCs (PDMCs) (Figure 6A).
PMA + ionomycin stimulation was also a potent inducer of MC
IL-2 secretion, demonstrating that MCs have the capacity to
produce copious amounts of IL-2. To confirm these findings
in vivo, we analyzed expression of IL-2 in splenic MCs from
mice with dermatitis by flow cytometry (Figure 6B). Importantly,
immunofluorescent staining (Figure 6C) of spleen sections from
i.v. reconstituted KitW-sh/W-sh mice, via either Il2+/+ or Il2/
MCs, formally demonstrated the in situ production of IL-2 by
MCs in the spleen (Figure 6C). Further quantitative analysis re-
vealed that the total numbers of splenic MCs producing IL-2
wasmarkedly increased during the course of disease (Figure 6D).
In contrast, the numbers of splenic basophils (CD117-FceRI+
CD49b+) decreased upon oxazolone challenge (data not shown),
ruling out these cells as a confounding factor in the accumulation
of MCs in the spleen.
To directly assess the role of splenic MC IL-2 production in
controlling the severity of disease KitW-sh/W-sh mice, reconsti-
tuted i.v. with MCs from Il2/ or from WT littermates were chal-
lenged with oxazolone. In contrast to the mice carrying WTMCs,
the loss of IL-2 production by MCs resulted in an increased
severity of disease (Figure 7A). We hypothesized that this may
be due to a compromised balance of activated T cells to Treg
cells relative to the general CD4+ response. Analysis of cells
from tissues of mice with dermatitis disclosed no difference in
CD4+, CD4+ Foxp3+, and the activated- to regulatory-T cell ratio
(Tact cell:Treg cell), in the spleen and lymph node, forWTmice or
KitW-sh/W-sh mice carrying IL-2-producing or -deficient MCs (Fig-
ure 7B). In mice with Il2/ MCs, there was also no difference in
the proportion of CD4+ T cells in the ear. Nonetheless, a decrease
Figure 7. SplenicMC IL-2 Production Controls the Ratio of Activated
T Cells:Treg Cells and Is Needed for Late-Stage Suppression of
Dermatitis
(A) Ear swelling in C57BL/6mice orKitW-sh/W-shmice reconstitutedwith Il2+/+ or
Il2/ MCs via an i.v. injection (n = 5).
(B) FACS analysis of total cell populations from tissues of KitW-sh/W-sh mice
after i.v. injection with either Il2+/+ or Il2/ MCs and induction of oxazolone
dermatitis (day 30). Activated T (Tact) cells are CD4+CD5+CD69+; regulatory
T (Treg) cells are CD4+Foxp3+.
Data are means ± SEM and significance was determined by two-way
ANOVA (A) and a two-tailed Student’s t test (B); *p < 0.05; **p < 0.01. See also
Figure S7.
Figure 6. Oxazolone Dermatitis Increases MC-IL-2 Production
In Vivo
(A) Quantitation of IL-2 production by in vitro stimulation of peritoneal- and
bone-marrow-derived MC (PDMC and BMMC, respectively) after FcεRI or
PMA + ionomycin stimulation. IL-2 was measured by ELISA.
(B) Flow cytometric detection of IL-2+ MCs in the spleen of BALB/c mice with
oxazolone dermatitis. This strain was preferred for cytometry over C57BL/6
because of the higher numbers of splenic MCs.
(C) Immunofluorescent detection of IL-2 production in KitW-sh/W-sh mice re-
constituted (i.v.) with BMMCs from Il2-/- and Il2+/+ mice. Double staining was
done with anti-IL-2 (green) and anti-CD117 (Kit) (red), as indicated. Scale bars
represent 30 mm.
(D) Total numbers of IL-2+ MCs was determined in spleens harvested from
BALB/c mice on days 0, 17, and 27 of oxazolone-induced dermatitis (n = 4).
Data are means ± SEM and significance was determined by a two-tailed
Student’s t test (A) or by two-way ANOVA (D); **p < 0.01; ***p < 0.001. See also
Figure S6.
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Mast Cell IL-2 Suppresses Dermatitisin the percent of CD4+Foxp3+ cells relative to total CD4+ cells
was observed with a significant (p < 0.05) increase in the ratio
between activated (CD4+CD5+CD69+) T cells and Treg cells (Fig-
ure 7B). Taken together, these data indicate that, in the absence
of MC IL-2, Treg cell expansion is sluggish compared to T cell
activation and CD4+ T cell proliferation, thus creating an imbal-
ance between the regulatory and effector responses. Histolog-
ical analysis confirmed comparable engraftment in the spleens
of the recipients of Il2+/+ and Il2/MCs (Figure S7B). These find-
ings demonstrate a previously unappreciated role for MCs, and
their IL-2-producing ability, in controlling the appropriate ratio
of activated T cells:Treg cells at the site of inflammation during
chronic allergic dermatitis.
DISCUSSION
There is increasing evidence of the importance of MC-T cell
crosstalk in regulating the immune response. MC effector
activity is suppressed by Treg cells (Gri et al., 2008) and Treg
cells can also use MCs as mediators of immune suppression(Lu et al., 2006). MCs have also been implicated in promoting
CD4+ and CD8+ T cell expansion (Piconese et al., 2009; Stelekati
et al., 2009). Herein, we describe a regulatory mechanism in
which secretion of IL-2 by MCs suppresses chronic allergic
dermatitis by enhancing the proportion of Treg cells at the site
of inflammation and decreasing the fraction of activated T cells
at this site.
It has been reported that MCs can either promote (Bieder-
mann et al., 2000; Bryce et al., 2005; Dudeck et al., 2011; Suto
et al., 2006) or dampen (Depinay et al., 2006; Grimbaldeston
et al., 2007; Hart et al., 1998) contact hypersensitivity, the latter
being mediated primarily through MC production of IL-10. Du-
deck and coworkers recently reported (Dudeck et al., 2011)
that MCs are key promoters of contact hypersensitivity and not
suppressors of this response. They induced contact hypersensi-
tivity in a manner similar to that reported in the Grimbaldeston
study (Grimbaldeston et al., 2007), using a mouse model
(Mcpt5-Cre+iDTR+) in which connective tissue type MCs are
selectively depleted. Their findings showed that the absence ofImmunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc. 567
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Mast Cell IL-2 Suppresses Dermatitisconnective tissue type MCs impaired migration of DCs to the
lymph nodes and caused a marked reduction in contact hyper-
sensitivity. They proposed that previous studies in mast cell-
deficient mice (KitW-sh/W-sh or KitW/W-v) showing MC-protective
effects were flawed because of potential immunological abnor-
malities in these mice. Although it is clear that KitW-sh/W-sh or
KitW/W-v mice have various abnormalities (Grimbaldeston et al.,
2005; Wolters et al., 2005), such overt dismissal for the role of
MCs as suppressors should be cautioned by the fact that
the particular disease model, mouse strain or genetics, route
of sensitization and challenge, and strength of stimulus can all
influence the immune response. In agreement with Dudeck
et al. (2011), we (data not shown) and others (Norman et al.,
2008; Suto et al., 2006) have seen that MCs can promote acute
contact hypersensitivity inKitW-sh/W-sh or KitW/W-v mice in models
where strength of the stimulus may be modest. Interestingly,
Norman et al. (2008) showed that induction of contact hypersen-
sitivity by a weak versus strong stimulus was a determinant of
whether MCs induce or suppress disease, respectively. In our
study, we utilize a model that differs from that used by Grimbal-
deston et al. (2005) and Dudeck et al. (2011) in that repeated
challenges of oxazolone on the ear were done for a period of
approximately 28 days. This chronic model shows many of the
characteristics of human AD (Leung et al., 2004) including the
presence of both Th1 and Th2 cell cytokines. Our finding of
MC-mediated suppression is consistent with the results of
Norman et al. (2008) where a strong stimulus induced both Th1
and Th2 cell cytokines and resulted in a protective role for
MCs. In addition, our findings also show that MCs can act to
cause suppression from tissues (spleen) distal to the site of
inflammation. Thus, one cannot exclude that the presence of
mucosal MCs, which are seemingly not depleted in the diph-
theria toxin-induced Mcpt5-Cre+iDTR+ mice, could also influ-
ence observed responses.
Our deduction that the spleen represents a site involved in MC
regulatory function is based on several findings. Splenectomized
mice had a diminished inflammatory response, and anti-CD25
treatment of these mice failed to exacerbate disease. This
demonstrated the contribution of the spleen in oxazolone-
induced inflammation and showed that the effect of anti-CD25
was dependent on the spleen. The effect of anti-CD25 treatment
was independent of MCs as shown by the fact that oxazolone-
induced dermatitis was markedly exacerbated in the MC-
deficient KitW-sh/W-sh mice. Intravenous MC reconstitution of
KitW-sh/W-sh mice, which causes engraftment of the spleen,
restored regulation of disease despite no engraftment of MCs
in ear pinna. It is important to note that i.v. reconstitution of
KitW-sh/W-sh mice with MCs engrafts several other sites (Grimbal-
deston et al., 2005; Wolters et al., 2005), including LNs (a key site
of MC-T cell interactions; Gri et al., 2008; Piconese et al., 2009),
and therefore these sites may be contributory. Migration of MCs
to the spleen was dependent on IgE accumulation in the spleen
andmirrored both the increased production of IL-2 byMCs in the
spleen and the suppression of disease. The precise mechanism
underlying the increase of MCs in the spleen has yet to be eluci-
dated. It does not appear to involve FcεRI, because mice defi-
cient in FcεRIb (and thus unable to express FceRI) showed
increased numbers of MCs in the spleen after oxazolone chal-
lenge (data not shown). However, antibody blockade of CD23 in-568 Immunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc.hibited the increase of splenic MCs (data not shown), suggesting
the possible involvement of this low-affinity IgE receptor. IgE
engagement of CD23 on monocytes (which infiltrate the spleen
upon oxazolone challenge; Sugiura et al., 2010) has been shown
to induce secretion of CCL3 (Ezeamuzie et al., 2009), a potent
chemoattractant for MCs. Collectively, these findings demon-
strate a connection between the spleen and the skin in modu-
lating chronic allergic dermatitis, and the putative trafficking of
Treg cells between the two sites warrants further investigation.
It should be noted that the spleen has also been shown to be
essential for the induction of antigen-specific allergic diarrhea
because of mobilization of primed splenic CD4+ T cells to the
large intestine (Kurashima et al., 2007). Moreover, migration of
MCs to the spleen is a well-described phenomenon: acute
models of DNFB (Wang et al., 1998) and peptidoglycan (Matsui
and Nishikawa, 2006) dermatitis and a model of helminth infec-
tion (Friend et al., 2000) showed increased numbers of MCs in
the spleen.MC-mediated regulation of disease severity at a loca-
tion distal to the site of inflammation was also shown in a mouse
model of experimental autoimmune encephalomyelitis, where
MCs exacerbated disease after adoptive transfer without repo-
pulating the inflammatory site, i.e., the central nervous system
(Tanzola et al., 2003). Thus, we propose that MC migration to
the spleen may be important beyond allergic skin disease.
Localization of Treg cell-MC interactions to a site such as the
spleen may provide an explanation of the observation that exog-
enous administration of IL-2 in postsensitized mice did not
modify disease course, whereas MC-derived IL-2 alleviates
chronic disease. We hypothesize that a systemic bolus of IL-2,
while disease is ongoing, may stimulate both regulatory and
effector T cells that express the IL-2R, thus failing to alter the
course or severity of disease. Conversely, a systemic bolus prior
to disease would target those cells constitutively expressing the
IL-2R, which are primarily Treg cells (Malek and Bayer, 2004),
and cause amplification of their activity, thus suppressing the
disease. The production of IL-2 by MCs at a distal lymphoid
organ may serve a similar role in compartmentalizing the effect
of IL-2 during the disease course. Our data do not define the
numbers of MCs required in order to maintain normal regulation
in dermatitis. In fact, comparable degrees of regulation were
obtained in C57BL/6 as in KitW-sh/W-sh mice after i.d. or i.v. injec-
tion of the latter with MCs. Although in C57BL/6 mice MC
numbers in the spleen (per 20 mm2) were in the range of 5–10,
i.d. reconstituted KitW-sh/W-sh showed 4- to 5-fold greater
numbers and for i.v. reconstituted KitW-sh/W-sh several hundreds
(Grimbaldeston et al., 2005; data not shown). Thus, the absolute
numbers of MCs migrating to the spleen does not appear to
affect the onset or extent of the suppressive regulatory effect
on disease. We also theorize that in the early phase of dermatitis
(or throughout disease course in the case of KitW-sh/W-sh mice),
IL-2 is provided by cells other than MCs. This is supported by
the finding of a small population of splenic CD4+ T cells (approx-
imately 0.8%) that stain positive for IL-2 in naive WT mice (data
not shown). However, unlike MCs, this population of T cells
did not expand during disease course. In addition, we detected
IL-2-producing cells in the spleens of non-MC-reconstituted
KitW-sh/W-sh mice with dermatitis. We cannot formally exclude
that some of the observed responses in KitW-sh/W-sh mice might
result from other described abnormalities in these mice beyond
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must conclude from the MC reconstitution of KitW-sh/W-sh mice
that IL-2 expression in MCs is vital for late-stage disease
suppression, but that it is not the rate-limiting factor in initiating
regulatory control.
Although our results indicate that Treg cells and MCs exert
comparable effects in suppressing the response to repeated ox-
azolone challenge, the overall impact on immune homeostasis
differs greatly. This is exemplified by comparing the severe
phenotype resulting from Treg cell deficiency in Foxp3sf mice
(Brunkow et al., 2001) and the mild phenotype associated with
the absence of MCs in KitW-sh/W-sh mice (Grimbaldeston et al.,
2005). Whereas Foxp3sf mice have a life span of 16–25 days,
KitW-sh/W-sh mice have a nearly normal life span. Foxp3sf mice
can develop a spontaneous and severe eczematous skin
disease (which made them unsuitable for our studies), whereas
KitW-sh/W-sh mice may show mild skin lesions in their late life.
In fact, the data argue that Treg cells do not require MCs to
suppress disease at early stages (prior to the fourth or fifth chal-
lenge); rather, their role appears to be in providing help to Treg
cells once disease has reached almost maximal severity. This
view is supported by the findings that inactivation of Treg cells
increases the numbers of splenic MCs in the spleen and that
consequent IL-2 production supports Treg cell numbers at the
site of inflammation.
In summary, we propose that MC-Treg cell communication
during the course of oxazolone-induced chronic allergic derma-
titis is vital to disease regulation. Our data argue that the spleen
plays a role in the inflammatory process and serves as a site
where MCs are recruited as second line regulators in an IgE-
dependent manner. By producing IL-2, MCs serve to maintain
the Treg:Teff cell ratio at the site of inflammation, which is man-
ifested by control of disease severity. Thus, the findings show
that MCs play an overall protective role in late stages of chronic
allergic dermatitis and suggest that failure of MC function in this
disease leads to increased severity.
EXPERIMENTAL PROCEDURES
Mice
For themajority of experiments, littermate and aged-matched (8–16week or as
indicated)WTmice of C57BL/6 backgroundwere usedwithKitW-sh/W-sh, Il2/,
and Igh-7/ mice. WT BALB/c mice were used as indicated. All mice were
purchased fromTaconicFarmsand the JacksonLaboratories.Splenectomized
C57BL/6 mice and normal controls were purchased from the Jackson Labo-
ratories. Mice were maintained and used in accordance with National
Institutes of Health (NIH) guidelines and National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases-approved animal study proposal A007-03-01.
Oxazolone-Induced Dermatitis
Micewere sensitized on day 0 by application of 15ml 1%oxazolone (Aldrich) in
acetone on both aspects of both ears (total of 60 ml per challenge per mouse).
Fromday 7, micewere challenged in the sameway with 0.5%oxazolone, three
times per week for up to a total of ten challenges. Under conditions where
disease was considerably exaggerated, the protocol was shortened. In control
mice, treatment was performed with acetone only. Ear thickness was
measured and recorded daily with a dial thickness gauge (Mitutoyo).
In Vivo Administration of Cytokines and Antibodies
Anti-mouse CD25 (clone B6.1), anti-mouse IL-2, and rat IgG1 were purchased
from BD Bioscience and IL-2 from PeproTec, Inc. Anti-CD25 or IgG1 isotype
control were injected intraperitoneally (i.p.) at doses of 300 mg per injection,either on day -1 (presensitization) or day 6 (postsensitization). Immune
complexes were prepared by incubating 1 mg anti-IL-2 with 2 mg IL-2 at
4C overnight with rotation. This solution was given i.p. in two separate
doses either on days -2 and -1 (presensitization) or on days 6 and 7
(postsensitization).
Histological Staining
Tissue samples were collected at the end of each experiment and placed
in formalin solution, 10% neutral buffered (Sigma-Aldrich). Embedding,
sectioning, H&E, and toluidine blue staining were done by American Histolabs.
Immunohistochemical analysis for IL-2-CD117(Kit) was done on formalin-fixed
paraffin-embedded tissues. Antigen retrieval was performed by a microwave
oven in either Tris-EDTA buffer (pH 9) or citrate-based antigen unmasking
solution (Vector Laboratories). Binding of an anti-Kit (Abcam) was detected
with an Alexa Fluor 568-conjugated secondary antibody. Detection of IL-2
was with Alexa Fluor 488-conjugated IL-2 antibody (Santa Cruz, 5 mg/mL) or
for control a similarly conjugated normal IgG. Stained sections were mounted
with an anti-fademedium (Vector Laboratories) and analyzed by confocal laser
scanning microscopy (LSM 510 Meta, Carl Zeiss, Germany).
Cytokine and IgE Titers
Tissues were homogenized in 700 ml PBS supplemented with complete
protease inhibitor cocktail tablets, 1 tablet/50 ml PBS (Roche Diagnostics).
After 10 min centrifugation at 14,0003 g (4C), the supernatant was collected
and kept at -80C. Total protein concentration wasmeasuredwith Bio-Rad DC
Protein Assay (Bio-Rad Laboartories) and cytokines titers were detected in 1:5
diluted homogenate samples with ExcelArray Mouse Inflammation Array I
(Pierce). Total IgE titers in tissue homogenates and in sera were determined
with mouse IgE ELISA quantitation kit (Bethyl Laboratories, Inc). Oxazolone-
specific IgE was measured in a semiquantitative ELISA. For coating, 2% oxa-
zolone was prepared in ethanol and added to 2% bovine serum albumin (BSA)
(MP Biomedicals) at a ratio of 3:50. The oxazolone/BSA mixture was diluted
1:10 in carbonate buffer and used for coating overnight at 4C. Blocking
was performed with 10% fetal bovine serum (FBS) (GIBCO) in PBS for 3 hr
at room temperature. Sera was diluted 1:10 in buffer prior to use. Buffers,
plates, antibodies, and HRP substrate were from Bethyl Laboratories, Inc.
For in vitro IL-2 detection, MCs were suspended at 5 3 106 cells per ml.
Activation was induced with antidintrophenyl-specific IgE and DNP-HSA
(Ag) or with 40 nM PMA (phorbol 12-myristate 13-acetate; Sigma) and
400 nM ionomycin (Calbiochem) for 6 hr at 37C. The supernatant was
analyzed with mouse IL-2 ELISA (eBioscience).
Generation of MCs and Reconstitution of Mice
Bone marrow-derived cultured MCs were generated as previously described
(Gonzalez-Espinosa et al., 2003). Differentiation of MCs was confirmed by
FACS analysis with c-Kit and FcεRI as markers. Cells were used when cultures
were more than 95% Kit+FcεRI+. MCs were injected at a concentration of 2 3
106 or 107 cells (as indicated) in 200ml RPMI either to the ear skin or into the tail
vein of 6- to 8-week-old male KitW-sh/W-sh recipients. Engraftment was allowed
for aminimum of 6 or 10 weeks depending on themethod of reconstitution (i.d.
or i.v., respectively). Subsequently, mice were subjected to oxazolone sensiti-
zation and challenge, after which reconstitution in all mice was confirmed by
toluidine blue staining of tissue sections.
Flow Cytometric Analysis
For determination of cells in the skin, ears were removed from mice and split
into dorsal and ventral halves. The skin was placed in 2ml digestion buffer con-
taining 0.1 mg/ml DNase I and 0.2 mg/ml Liberase TL (Roche Diagnostics)
diluted in 1% FBS in RPMI (GIBCO). After a 1 hr incubation at 37C, ears
were placed into a 70 mm cell strainer (BD Biosciences) and mashed through
the mesh. The strainers were washed with 2ml of 1% FBS, 2 mMEDTA in PBS
(GIBCO). Detection of cell surface markers and intracellular staining were
performed as previously described (Charles et al., 2009). Flow cytometry
acquisitions were done with a FACSCalibur (BD Biosciences) and Cell Quest
software. Analysis was with FlowJo software (Treestar, Inc.). For IL-2 intracel-
lular staining, cells were fixed with 3.7% paraformaldehyde solution in PBS,
permeabilized in PBS, 0.1% BSA, 0.1% saponin, and stained in the sameImmunity 35, 562–571, October 28, 2011 ª2011 Elsevier Inc. 569
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T cells was determined by Foxp3 staining (eBioscience).
Statistical Analysis
For comparisons between two populations, two-tailed Student’s t tests
were performed. Disease course was analyzed with a two-way ANOVA test.
p values less than 0.05 were considered statistically significant and the
following designation used: *p < 0.05; **p < 0.01; ***p < 0.001. Statistical
analysis was performed with Prism software (GraphPad Software, Inc.).
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